Emcure Expands Biosimilars Portfolio Under Leadership of MD Satish Mehta
Emcure Pharmaceuticals Aims to Capitalize on Patent Expiries with Biosimilars Expansion
Mumbai: Emcure Pharmaceuticals, a leading Indian pharmaceutical company, is planning to expand its biosimilars pipeline in response to a wave of patent expiries and growing global demand for these medications.
According to company executives, the decision to expand its biosimilars pipeline is driven by the impending patent expiries of several high-value biologics, which are expected to create a lucrative market for biosimilars. Emcure Pharmaceuticals aims to capitalize on this trend by developing and launching its own biosimilars portfolio.
The company's strategy is to focus on developing biosimilars for key therapeutic areas, including oncology, immunology, and diabetes. By doing so, Emcure Pharmaceuticals hopes to tap into the growing demand for biosimilars, which is expected to continue in the coming years.
Read also: Wockhardt Secures Second US Approval for New Drug, Eyes Commercial Viability
Key Statistics
| Company | Biosimilars Pipeline Size (as of 2023) |
|---|---|
| Emcure Pharmaceuticals | N/A (planning to expand) |
| Other leading biosimilars manufacturers | 20-30 products |
Emcure Pharmaceuticals' decision to expand its biosimilars pipeline is a strategic move to stay ahead of the competition and capitalize on the growing market demand. The company's efforts are expected to pay off in the coming years, as the global biosimilars market continues to grow and mature.
Investor Takeaway
Emcure Pharmaceuticals is expanding its biosimilars portfolio, which could be a positive development for the company.
More in General
Wockhardt Secures Second US Approval for New Drug, Eyes Commercial Viability
US FDA Approves Wockhardt's Zaynich for Treatment of Complicated Urinary Tract Infections in Adults
Indoco Remedies Shares Gain Focus Following EU GMP Certification for Baddi Facility
